Psoriasis

JDD June 2023 Issue Highlights
acneThe June issue of the Journal of Drugs in Dermatology (JDD) features original articles with topics ranging from pediatric acne, rosacea, androgenetic alopecia, precision medicine, infantile hemangiomas, and many more.  Check out this month’s issue highlights straight from the JDD Editor’s desk: The Many Faces of Pediatric Acne: A Practical Algorithm for Treatment, Maintenance Therapy, and …
acne
Scaly Papules – Friday Pop Quiz 3/31/2023
A 55-year-old patient from the Caribbean presents with indurated scaly papules and plaques on his trunk, arms, and legs. The rash started six months ago and has progressed rather quickly. Review of system was notable for pruritus and xerosis; patient reported no personal history of skin diseases, including psoriasis and atopic dermatitis. Several 4-mm punch biopsies were performed. Based on th …
Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy
psoriasis Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment Danielle Rinck MDa, Elaine Siegfried MDb aBeth Israel Deaconess Medical Center, Boston, MA | bSaint Louis University School of Medicine, St. Louis, MO J Drugs Dermatol. 2022;21(8):897-899. doi:10.36849/JDD.6888   A previously healthy 3-year-old boy presented to our Pediatric Derm …
psoriasis
Apremilast Therapeutic Cheat Sheet
apremilastApremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica …
apremilast
JDD February 2023 Issue Highlights
The February issue of the Journal of Drugs in Dermatology (JDD) includes the perfect blend of original articles, case reports, and brief communications exploring topics such as efficacy and safety of 1% clascoterone cream in patients aged ≥12 years with acne vulgaris, dupilumab’s impact on atopic dermatitis among adolescent and adult patients, development and validation of a photonumeric scale …